The 2022 American Association of Clinical Endocrinology (AACE) guidelines [65] and the 2022 ADA and Kidney Disease: Improving Global Outcomes (KDIGO) joint consensus [66] recommend the use of finerenone in persons with T2D, an estimated glomerular filtration rate ≥25 mL/min/1.73 m2, normal serum potassium concentration, and albuminuria (urine albumin-creatinine ratio ≥30 mg/g) despite a maximum tolerated dose of a renin-angiotensin system blocker (grade A). This evidence concerns the gene ALB and kidney disorder.